MARCH8 antibody

GeneTex

MARCH8 antibody

9

WB: 0.5 - 1 microg/mL. ICC/IF: 2.5 microg/mL. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.

ImmunoFluorescence, Western Blot, ELISA, ImmunoCytoChemistry

Research Use Only

Polyclonal

1 mg/ml

Unconjugated

MARCHF8

membrane associated ring-CH-type finger 8

cellular modulator of immune recognition (c-MIR); CMIR; c-MIR; c-mir, cellular modulator of immune recognition; E3 ubiquitin-protein ligase MARCH8; E3 ubiquitin-protein ligase MARCHF8; MARCH8; MARCH-VIII; membrane associated ring finger 8; membrane-associated ring finger (C3HC4) 8, E3 ubiquitin protein ligase; membrane-associated RING finger protein 8; membrane-associated RING-CH protein VIII; MIR; RING finger protein 178; RING-type E3 ubiquitin transferase MARCH8; RING-type E3 ubiquitin transferase MARCHF8; RNF178

Rabbit

IgG

E3 ubiquitin-protein ligase MARCH8

MARCH8 (c-MIR) is a novel E3 ubiquitin ligase designated as the modulator of immune recognition (MIR) family, whose catalytic domain is a variant RING domain (RING-CH domain). MARCH8 was found as a functional and structural homolog of KSHV MIR1 and MIR2. MARCH8 targets B7-2 to lysosomal degradation and down-regulates the B7-2 surface expression through ubiquitination of its cytoplasmic tail. Furthermore, MARCH8 has been shown to down-regulate the expression of transferrin receptor and Fas, an important molecule for the induction of apoptosis. MARCH8 is the first example of an E3 ubiquitin ligase that is capable of inhibiting MHC II expression. Recent findings suggest that MARCH8 may regulate immune responses by promoting ubiquitination of MHC-II and CD86, leading to their subsequent endocytosis and lysosomal degradation.

-20°C or -80°C,2°C to 8°C

12352203